CTNNB1 and breast carcinoma: The WNT/beta-catenin signaling pathway is altered in more than 90% of patients with CRC [2] as well as in patients with breast cancer [53, 54] and hepatocellular carcinoma [55] making it a particularly attractive therapeutic target.